MTR 103
Alternative Names: MTR-103Latest Information Update: 16 May 2023
At a glance
- Originator Midatech
- Developer Biodexa Pharmaceuticals; Dana-Farber Cancer Institute
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Glioblastoma in United Kingdom
- 28 Jun 2020 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 25 Jan 2019 MTR 103 licensed to China medical System in China, Hong Kong, Macau and Taiwan